

# Annick Rousseau

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8701865/annick-rousseau-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51  
papers

1,753  
citations

26  
h-index

41  
g-index

53  
ext. papers

1,950  
ext. citations

4.5  
avg, IF

3.92  
L-index

#	Paper	IF	Citations
51	The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2016</b> , 27, 942-51	12.7	147
50	Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. <i>Clinical Pharmacokinetics</i> , <b>2009</b> , 48, 805-16	6.2	103
49	Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 354-61	3.2	84
48	Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. <i>Fundamental and Clinical Pharmacology</i> , <b>2002</b> , 16, 253-62	3.1	83
47	Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. <i>British Journal of Clinical Pharmacology</i> , <b>2011</b> , 71, 391-402	3.8	79
46	Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. <i>Hepatology</i> , <b>2008</b> , 47, 1453-61	11.2	75
45	Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 609-19	3.2	73
44	Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. <i>Clinical Pharmacokinetics</i> , <b>2010</b> , 49, 683-92	6.2	71
43	A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. <i>Clinical Pharmacokinetics</i> , <b>2005</b> , 44, 837-47	6.2	53
42	Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. <i>Clinical Pharmacokinetics</i> , <b>2006</b> , 45, 1135-48	6.2	53
41	Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. <i>Clinical Pharmacokinetics</i> , <b>2012</b> , 51, 175-86	6.2	49
40	Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. <i>Clinical Pharmacokinetics</i> , <b>2002</b> , 41, 71-80	6.2	49
39	Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. <i>Clinical Pharmacokinetics</i> , <b>2009</b> , 48, 745-58	6.2	46
38	Adaptive control methods for the dose individualisation of anticancer agents. <i>Clinical Pharmacokinetics</i> , <b>2000</b> , 38, 315-53	6.2	43
37	Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. <i>Pharmacogenetics and Genomics</i> , <b>2010</b> , 20, 537-43	1.9	42
36	Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. <i>Clinical Pharmacokinetics</i> , <b>2005</b> , 44, 1317-28	6.2	42
35	A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 477-84	3.8	42

34	Relationship between psychotropic drugs and thyroid function: a review. <i>Toxicology and Applied Pharmacology</i> , <b>1998</b> , 149, 127-35	4.6	41
33	Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry. <i>Therapeutic Drug Monitoring</i> , <b>2006</b> , 28, 274-7	3.2	39
32	Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 129-35	3.2	39
31	Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. <i>British Journal of Clinical Pharmacology</i> , <b>2010</b> , 69, 675-83	3.8	36
30	Ribavirin: Past, present and future. <i>World Journal of Hepatology</i> , <b>2016</b> , 8, 123-30	3.4	35
29	Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 285-94	3.2	34
28	Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. <i>American Journal of Transplantation</i> , <b>2005</b> , 5, 1477-82	8.7	33
27	Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma. <i>Clinical Pharmacokinetics</i> , <b>2002</b> , 41, 1095-104	6.2	30
26	Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. <i>Clinical Pharmacokinetics</i> , <b>2006</b> , 45, 905-22	6.2	27
25	Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2011</b> , 18, 19-24	2.7	23
24	Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants. <i>Pharmacological Research</i> , <b>2011</b> , 63, 1-7	10.2	22
23	Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions. <i>Transplantation</i> , <b>2003</b> , 76, 683-8	1.8	22
22	Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients. <i>Clinical Pharmacokinetics</i> , <b>2012</b> , 51, 29-39	6.2	21
21	Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships. <i>Pharmacological Research</i> , <b>2011</b> , 63, 432-8	10.2	18
20	Development and evaluation of a simulation procedure to take into account various assays for the Bayesian dose adjustment of tacrolimus. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 171-7	3.2	18
19	Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation. <i>Transplantation</i> , <b>2016</b> , 100, 640-7	1.8	18
18	eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?. <i>Liver International</i> , <b>2015</b> , 35, 71-8	7.9	16
17	Synthesis and antithyroid activity of pyridine, pyrimidine and pyrazine derivatives of thiazole-2-thiol and 2-thiazoline-2-thiol. <i>Chemical and Pharmaceutical Bulletin</i> , <b>1993</b> , 41, 1258-60	1.9	14

16	Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 277-88	6.2	13
15	Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, 850-5	3.3	13
14	Cost-effectiveness analysis of individualized mycophenolate mofetil dosing in kidney transplant patients in the APOMYGRE trial. <i>Transplantation</i> , <b>2010</b> , 89, 1255-62	1.8	12
13	Anti-hepatitis C virus drugs and kidney. <i>World Journal of Hepatology</i> , <b>2016</b> , 8, 1343-1353	3.4	12
12	Anti-inflammatory action of methimazole. <i>Pharmacology</i> , <b>1997</b> , 55, 173-8	2.3	11
11	Spectroscopic analysis of charge transfer complex formation and peroxidase inhibition with tricyclic antidepressant drugs: potential anti-thyroid action. <i>Biological and Pharmaceutical Bulletin</i> , <b>1996</b> , 19, 726-33	2.3	11
10	Adherence profiles in kidney transplant patients: Causes and consequences. <i>Patient Education and Counseling</i> , <b>2020</b> , 103, 189-198	3.1	11
9	Influence of sampling-time error on cyclosporine measurements nominally at 2 hours after administration. <i>Clinical Chemistry</i> , <b>2003</b> , 49, 813-5	5.5	9
8	Stability of ribavirin concentrations depending on the type of blood collection tube and preanalytical conditions. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 237-41	3.2	9
7	An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine. <i>Toxicology and Applied Pharmacology</i> , <b>2002</b> , 183, 189-97	4.6	8
6	Thyroid accumulation and adverse effects of imipramine and desipramine in rats after long-term administration. <i>Pharmacology</i> , <b>1998</b> , 57, 242-8	2.3	8
5	Evaluation of Longitudinal Exposure to Tacrolimus as a Risk Factor of Chronic Kidney Disease Occurrence Within the First-year Post-Liver Transplantation. <i>Transplantation</i> , <b>2021</b> , 105, 1585-1594	1.8	3
4	Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 684-692	3.2	2
3	Modelling ciclosporin double-peak absorption profiles in the early post-transplantation period. <i>Clinical Pharmacokinetics</i> , <b>2004</b> , 43, 1055-7	6.2	2
2	Validation of the psychometrics properties of a French quality of life questionnaire among a cohort of renal transplant recipients less than one year. <i>Quality of Life Research</i> , <b>2016</b> , 25, 2347-59	3.7	
1	A comparison of the effect of cyclosporin and sirolimus on the pharmacokinetics of mycophenolate in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 061120055829076	3.8	